Manufacturing & Packaging

Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.

New 25,000 square-foot facility will help grow customers’ gene therapy programs.

Facility addition expected to increase production capacity of TNAs.

cGMP line will fill vials, syringes, and cartridges, while supporting small-scale commercial production.

South Korea facility expected to provide fill-finish capabilities.

New California plant expected to streamline medicine production.

Investment expected to establish additional cGMPs, expand CDMO services.

Joint venture expected to address pharma’s injectable drug-filling sector.

Collaboration to support biotech company’s clinical and commercial production efforts.

Plant is expected to offer packaging, serialization, and third-party contract manufacturing services.

Saint-Beauzire complex dedicated to sterile liquid drug production.

The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

CDMO is commissioning third GMP biologics facility in Fremont.

CDMO will be providing high-quality lentiviral vectors for CAR-T therapies.

Location serves as the US flagship for company’s global pharma development network.

Project—which is expected to double plant’s distribution capacity—will be completed by end of Q3.

Complex to develop cGMP-compliant, commercial-scale plasmid DNA.

Companies to release variety of options for this sector.

Expansion expected to help tackle health issues at a faster rate, company says

Transaction expected to close early this year

Creates Cellular Origins in order to simplify the late-stage development process

North Carolina facility to manufacture Pfizer’s pipeline products

Nottingham location expected to be fully operational by the end of 2023

Platform is expected to streamline batch turnaround times

Acquisition of Texas facility to add 60,000 square feet of manufacturing space to company’s footprint

Provider will be CDMO’s primary material supplier in the lab, clinical, and production settings

Award given in recognition of CDMO’s commitment to promoting sustainable future

Phoenix location will be company’s first to focus on high-density microarrays for diagnostic and life science research

CDMO will be able to produce rAAV commercial grade product

Provides clientele with an augmented drug development solution